Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 348 | 2025 | 11879 | 16.140 |
Why?
|
Stroke Volume | 240 | 2025 | 5622 | 10.500 |
Why?
|
Angiotensin Receptor Antagonists | 90 | 2024 | 1064 | 7.950 |
Why?
|
Tetrazoles | 78 | 2024 | 923 | 7.580 |
Why?
|
Biphenyl Compounds | 83 | 2024 | 1026 | 6.540 |
Why?
|
Spironolactone | 37 | 2024 | 415 | 5.710 |
Why?
|
Enalapril | 39 | 2024 | 317 | 4.810 |
Why?
|
Naphthyridines | 16 | 2025 | 185 | 3.900 |
Why?
|
Drug Combinations | 75 | 2024 | 2089 | 3.890 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 52 | 2024 | 1514 | 3.700 |
Why?
|
Glucosides | 33 | 2024 | 533 | 3.050 |
Why?
|
Ventricular Function, Left | 73 | 2025 | 3941 | 2.890 |
Why?
|
Benzhydryl Compounds | 40 | 2024 | 944 | 2.870 |
Why?
|
Hyperkalemia | 13 | 2024 | 234 | 2.770 |
Why?
|
Hospitalization | 88 | 2025 | 10847 | 2.660 |
Why?
|
Natriuretic Peptide, Brain | 36 | 2024 | 1751 | 2.350 |
Why?
|
Neprilysin | 22 | 2024 | 487 | 2.320 |
Why?
|
Ventricular Dysfunction, Left | 28 | 2024 | 2145 | 2.200 |
Why?
|
Diuretics | 18 | 2024 | 614 | 2.120 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 7 | 2023 | 158 | 1.820 |
Why?
|
Peptide Fragments | 30 | 2024 | 5151 | 1.630 |
Why?
|
Pulmonary Artery | 12 | 2022 | 1945 | 1.510 |
Why?
|
Double-Blind Method | 72 | 2025 | 12467 | 1.410 |
Why?
|
Glomerular Filtration Rate | 21 | 2025 | 2228 | 1.400 |
Why?
|
Antihypertensive Agents | 18 | 2024 | 2027 | 1.400 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 7 | 2023 | 252 | 1.260 |
Why?
|
Aged | 209 | 2025 | 171786 | 1.230 |
Why?
|
Anemia | 12 | 2023 | 1517 | 1.220 |
Why?
|
Diabetes Mellitus, Type 2 | 35 | 2024 | 12253 | 1.170 |
Why?
|
Humans | 408 | 2025 | 768970 | 1.170 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 14 | 2020 | 428 | 1.120 |
Why?
|
Potassium | 8 | 2025 | 1315 | 1.110 |
Why?
|
Hypotension | 9 | 2024 | 888 | 1.020 |
Why?
|
Heart-Assist Devices | 5 | 2023 | 1292 | 1.010 |
Why?
|
Middle Aged | 190 | 2025 | 223737 | 0.980 |
Why?
|
Renal Insufficiency, Chronic | 17 | 2024 | 2297 | 0.980 |
Why?
|
Cardiac Resynchronization Therapy | 5 | 2020 | 560 | 0.980 |
Why?
|
Fumarates | 12 | 2020 | 132 | 0.970 |
Why?
|
Male | 238 | 2025 | 365203 | 0.950 |
Why?
|
Angiotensinogen | 2 | 2024 | 161 | 0.890 |
Why?
|
Hypertension | 15 | 2024 | 8617 | 0.880 |
Why?
|
Treatment Outcome | 102 | 2025 | 65480 | 0.880 |
Why?
|
Female | 236 | 2025 | 397515 | 0.880 |
Why?
|
Prognosis | 68 | 2024 | 30046 | 0.870 |
Why?
|
Hypokalemia | 5 | 2019 | 152 | 0.850 |
Why?
|
Amides | 12 | 2020 | 452 | 0.840 |
Why?
|
Cause of Death | 18 | 2024 | 3721 | 0.800 |
Why?
|
Patient Readmission | 7 | 2018 | 3313 | 0.790 |
Why?
|
Natriuretic Peptides | 5 | 2023 | 156 | 0.790 |
Why?
|
Disease Management | 7 | 2019 | 2537 | 0.780 |
Why?
|
Cardiac Output, Low | 2 | 2017 | 192 | 0.780 |
Why?
|
Defibrillators, Implantable | 8 | 2021 | 1498 | 0.780 |
Why?
|
Guideline Adherence | 4 | 2024 | 2241 | 0.750 |
Why?
|
Kidney Diseases | 7 | 2023 | 2100 | 0.740 |
Why?
|
Cardiomyopathies | 9 | 2023 | 2057 | 0.730 |
Why?
|
Nutrition Assessment | 3 | 2024 | 740 | 0.720 |
Why?
|
Palliative Care | 6 | 2024 | 3644 | 0.720 |
Why?
|
Angiotensins | 3 | 2023 | 141 | 0.720 |
Why?
|
Cardiovascular Diseases | 31 | 2024 | 15661 | 0.710 |
Why?
|
Heart Failure, Diastolic | 5 | 2023 | 77 | 0.710 |
Why?
|
Atrial Fibrillation | 14 | 2023 | 5176 | 0.700 |
Why?
|
Death, Sudden, Cardiac | 12 | 2021 | 1568 | 0.670 |
Why?
|
Troponin T | 6 | 2023 | 787 | 0.660 |
Why?
|
Temporal Arteries | 2 | 2017 | 155 | 0.660 |
Why?
|
Cardiac Resynchronization Therapy Devices | 3 | 2020 | 122 | 0.650 |
Why?
|
Randomized Controlled Trials as Topic | 30 | 2024 | 10400 | 0.630 |
Why?
|
Edema, Cardiac | 1 | 2018 | 19 | 0.630 |
Why?
|
Kidney | 12 | 2024 | 7058 | 0.620 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2020 | 325 | 0.620 |
Why?
|
Monitoring, Ambulatory | 3 | 2022 | 358 | 0.610 |
Why?
|
Benzimidazoles | 8 | 2020 | 864 | 0.600 |
Why?
|
Aged, 80 and over | 52 | 2024 | 59739 | 0.590 |
Why?
|
Exanthema | 1 | 2022 | 503 | 0.590 |
Why?
|
Prospective Studies | 54 | 2024 | 54962 | 0.580 |
Why?
|
Renin | 6 | 2016 | 648 | 0.570 |
Why?
|
Hematinics | 7 | 2017 | 282 | 0.570 |
Why?
|
Cachexia | 1 | 2019 | 202 | 0.570 |
Why?
|
Furosemide | 7 | 2023 | 174 | 0.560 |
Why?
|
Heart Failure, Systolic | 4 | 2023 | 134 | 0.560 |
Why?
|
Hydrazones | 1 | 2017 | 105 | 0.550 |
Why?
|
Shock, Cardiogenic | 1 | 2022 | 711 | 0.550 |
Why?
|
Social Work | 1 | 2018 | 158 | 0.550 |
Why?
|
Quality of Life | 27 | 2024 | 13510 | 0.540 |
Why?
|
Giant Cell Arteritis | 2 | 2017 | 307 | 0.540 |
Why?
|
Pulmonary Wedge Pressure | 2 | 2020 | 276 | 0.540 |
Why?
|
Stroke | 13 | 2023 | 9756 | 0.530 |
Why?
|
Hemodynamics | 12 | 2024 | 4199 | 0.510 |
Why?
|
Heart Valve Diseases | 3 | 2023 | 1030 | 0.490 |
Why?
|
Ambulatory Care | 6 | 2019 | 2784 | 0.490 |
Why?
|
Blood Pressure | 15 | 2024 | 8544 | 0.490 |
Why?
|
Patient Dropouts | 2 | 2016 | 411 | 0.470 |
Why?
|
Home Care Services | 2 | 2012 | 660 | 0.470 |
Why?
|
Renin-Angiotensin System | 4 | 2020 | 736 | 0.470 |
Why?
|
Hyperemia | 1 | 2015 | 224 | 0.460 |
Why?
|
Troponin I | 1 | 2018 | 662 | 0.450 |
Why?
|
Aorta | 2 | 2013 | 2046 | 0.440 |
Why?
|
Patient Care Planning | 2 | 2019 | 904 | 0.440 |
Why?
|
Advance Care Planning | 2 | 2020 | 698 | 0.430 |
Why?
|
Adrenergic beta-Antagonists | 7 | 2024 | 1243 | 0.430 |
Why?
|
Risk Assessment | 22 | 2023 | 24333 | 0.430 |
Why?
|
Electrocardiography, Ambulatory | 1 | 2015 | 582 | 0.420 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2020 | 954 | 0.420 |
Why?
|
Diabetic Nephropathies | 4 | 2015 | 973 | 0.420 |
Why?
|
Diabetes Mellitus | 10 | 2025 | 5892 | 0.410 |
Why?
|
Coronary Stenosis | 2 | 2017 | 802 | 0.410 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3118 | 0.400 |
Why?
|
Practice Guidelines as Topic | 7 | 2024 | 7460 | 0.400 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3241 | 0.400 |
Why?
|
Follow-Up Studies | 34 | 2024 | 39394 | 0.400 |
Why?
|
Ventricular Remodeling | 4 | 2024 | 1282 | 0.390 |
Why?
|
Vascular Resistance | 2 | 2012 | 939 | 0.390 |
Why?
|
Polypharmacy | 3 | 2024 | 307 | 0.390 |
Why?
|
Sodium | 5 | 2022 | 1597 | 0.380 |
Why?
|
Cardiovascular Agents | 6 | 2019 | 849 | 0.380 |
Why?
|
Survival Rate | 24 | 2021 | 12873 | 0.380 |
Why?
|
Diastole | 4 | 2014 | 785 | 0.370 |
Why?
|
Patient Care Team | 2 | 2020 | 2528 | 0.370 |
Why?
|
Surgical Procedures, Operative | 1 | 2022 | 1941 | 0.360 |
Why?
|
Albuminuria | 5 | 2018 | 658 | 0.360 |
Why?
|
Triage | 3 | 2018 | 997 | 0.360 |
Why?
|
Pheochromocytoma | 2 | 2009 | 328 | 0.360 |
Why?
|
Infusions, Intravenous | 5 | 2019 | 2231 | 0.360 |
Why?
|
Drug-Eluting Stents | 3 | 2017 | 681 | 0.360 |
Why?
|
Coronary Occlusion | 1 | 2013 | 306 | 0.350 |
Why?
|
Telemedicine | 3 | 2020 | 3110 | 0.350 |
Why?
|
Prediabetic State | 3 | 2022 | 548 | 0.350 |
Why?
|
Hemoglobins | 3 | 2013 | 1531 | 0.350 |
Why?
|
Diabetic Angiopathies | 3 | 2015 | 806 | 0.340 |
Why?
|
Proportional Hazards Models | 15 | 2024 | 12562 | 0.340 |
Why?
|
Electrocardiography | 11 | 2024 | 6413 | 0.330 |
Why?
|
Growth Differentiation Factor 15 | 3 | 2023 | 199 | 0.330 |
Why?
|
Cardiomyopathy, Dilated | 4 | 2023 | 843 | 0.330 |
Why?
|
Glucocorticoids | 3 | 2017 | 2167 | 0.330 |
Why?
|
Cardiology | 4 | 2019 | 1701 | 0.330 |
Why?
|
Patient Admission | 2 | 2018 | 1370 | 0.330 |
Why?
|
Obesity | 9 | 2024 | 13091 | 0.320 |
Why?
|
Intermittent Claudication | 3 | 2017 | 305 | 0.320 |
Why?
|
Monitoring, Physiologic | 2 | 2021 | 1798 | 0.320 |
Why?
|
Risk Factors | 45 | 2024 | 74976 | 0.310 |
Why?
|
Patient Discharge | 4 | 2023 | 3491 | 0.310 |
Why?
|
Comorbidity | 14 | 2023 | 10592 | 0.310 |
Why?
|
Death, Sudden | 2 | 2022 | 301 | 0.310 |
Why?
|
Influenza Vaccines | 3 | 2022 | 781 | 0.300 |
Why?
|
Microcirculation | 1 | 2013 | 1281 | 0.300 |
Why?
|
Disease Progression | 10 | 2024 | 13674 | 0.300 |
Why?
|
Terminal Care | 2 | 2020 | 1772 | 0.290 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 5 | 2023 | 3253 | 0.290 |
Why?
|
Societies, Medical | 3 | 2019 | 3968 | 0.290 |
Why?
|
Pregnancy Complications | 3 | 2010 | 2974 | 0.290 |
Why?
|
Adrenal Gland Neoplasms | 2 | 2009 | 735 | 0.280 |
Why?
|
Algorithms | 7 | 2025 | 14201 | 0.280 |
Why?
|
Kaplan-Meier Estimate | 14 | 2024 | 6547 | 0.280 |
Why?
|
Heart Arrest | 6 | 2019 | 1515 | 0.280 |
Why?
|
Thrombosis | 2 | 2013 | 2956 | 0.280 |
Why?
|
Dose-Response Relationship, Drug | 13 | 2021 | 10765 | 0.280 |
Why?
|
Fibrinolysis | 1 | 2008 | 331 | 0.280 |
Why?
|
RNA Interference | 3 | 2024 | 2835 | 0.270 |
Why?
|
Pandemics | 6 | 2023 | 8749 | 0.270 |
Why?
|
Single-Blind Method | 7 | 2019 | 1586 | 0.260 |
Why?
|
Pain | 2 | 2017 | 5100 | 0.250 |
Why?
|
Ambulatory Care Facilities | 3 | 2019 | 941 | 0.250 |
Why?
|
Time Factors | 22 | 2024 | 40261 | 0.250 |
Why?
|
Clinical Trials as Topic | 8 | 2024 | 8055 | 0.250 |
Why?
|
Uric Acid | 3 | 2023 | 806 | 0.240 |
Why?
|
Coronary Disease | 3 | 2018 | 5919 | 0.240 |
Why?
|
Endpoint Determination | 2 | 2018 | 594 | 0.240 |
Why?
|
Directive Counseling | 1 | 2006 | 171 | 0.240 |
Why?
|
Myocardium | 3 | 2013 | 4790 | 0.240 |
Why?
|
Coronary Angiography | 6 | 2018 | 4541 | 0.240 |
Why?
|
Influenza, Human | 3 | 2022 | 1542 | 0.230 |
Why?
|
Morbidity | 8 | 2020 | 1757 | 0.230 |
Why?
|
Silicates | 1 | 2024 | 49 | 0.230 |
Why?
|
American Heart Association | 2 | 2019 | 1051 | 0.230 |
Why?
|
Cardiomyopathy, Hypertrophic | 2 | 2017 | 1335 | 0.220 |
Why?
|
Kidney Failure, Chronic | 3 | 2016 | 2493 | 0.220 |
Why?
|
Sleep Apnea Syndromes | 2 | 2012 | 984 | 0.220 |
Why?
|
Chronic Disease | 10 | 2024 | 9384 | 0.220 |
Why?
|
Coronary Artery Disease | 6 | 2018 | 6569 | 0.220 |
Why?
|
Dihydropyridines | 1 | 2023 | 67 | 0.220 |
Why?
|
United States | 32 | 2025 | 73186 | 0.220 |
Why?
|
Health Status | 6 | 2023 | 4095 | 0.220 |
Why?
|
Cardiotonic Agents | 3 | 2018 | 544 | 0.220 |
Why?
|
Sex Factors | 11 | 2025 | 10633 | 0.220 |
Why?
|
North America | 7 | 2024 | 1290 | 0.210 |
Why?
|
Aortic Diseases | 1 | 2009 | 741 | 0.210 |
Why?
|
Erythrocyte Indices | 1 | 2023 | 143 | 0.210 |
Why?
|
Predictive Value of Tests | 12 | 2021 | 15471 | 0.210 |
Why?
|
Protease Inhibitors | 2 | 2016 | 752 | 0.210 |
Why?
|
Incidence | 12 | 2021 | 21547 | 0.200 |
Why?
|
Telemetry | 2 | 2016 | 200 | 0.200 |
Why?
|
Malnutrition | 2 | 2019 | 632 | 0.200 |
Why?
|
Heart Ventricles | 5 | 2019 | 3840 | 0.200 |
Why?
|
Research Design | 3 | 2023 | 6214 | 0.200 |
Why?
|
Europe | 8 | 2024 | 3441 | 0.190 |
Why?
|
Injections, Subcutaneous | 1 | 2023 | 687 | 0.190 |
Why?
|
Echocardiography | 10 | 2019 | 5047 | 0.190 |
Why?
|
Drug Therapy, Combination | 11 | 2024 | 6320 | 0.190 |
Why?
|
Hypoglycemic Agents | 6 | 2024 | 3110 | 0.190 |
Why?
|
Aortic Valve | 2 | 2008 | 1969 | 0.190 |
Why?
|
Hypertension, Pulmonary | 1 | 2012 | 1601 | 0.190 |
Why?
|
Systole | 7 | 2020 | 937 | 0.190 |
Why?
|
Renal Insufficiency | 2 | 2018 | 812 | 0.190 |
Why?
|
Erythropoietin | 3 | 2015 | 718 | 0.180 |
Why?
|
Endothelium, Vascular | 1 | 2013 | 4428 | 0.180 |
Why?
|
Receptors, Angiotensin | 1 | 2021 | 141 | 0.180 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2019 | 2056 | 0.180 |
Why?
|
Myocardial Infarction | 8 | 2024 | 11521 | 0.180 |
Why?
|
Coronary Artery Bypass | 4 | 2021 | 2194 | 0.180 |
Why?
|
Patient Selection | 3 | 2014 | 4265 | 0.170 |
Why?
|
Bundle-Branch Block | 2 | 2020 | 278 | 0.170 |
Why?
|
Metanephrine | 2 | 2009 | 25 | 0.170 |
Why?
|
Sarcoidosis | 2 | 2019 | 535 | 0.170 |
Why?
|
Heart Valve Prosthesis | 1 | 2008 | 1468 | 0.170 |
Why?
|
Creatinine | 6 | 2024 | 1917 | 0.170 |
Why?
|
Communication | 2 | 2024 | 3908 | 0.160 |
Why?
|
Aftercare | 2 | 2023 | 921 | 0.160 |
Why?
|
Angina, Unstable | 1 | 2003 | 893 | 0.160 |
Why?
|
Russia | 5 | 2018 | 386 | 0.160 |
Why?
|
Syncope | 3 | 2018 | 430 | 0.160 |
Why?
|
Angiotensin II Type 2 Receptor Blockers | 1 | 2018 | 8 | 0.160 |
Why?
|
Catecholamines | 2 | 2010 | 389 | 0.160 |
Why?
|
Electronic Health Records | 3 | 2025 | 4879 | 0.160 |
Why?
|
Diet | 2 | 2023 | 8088 | 0.160 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2020 | 241 | 0.150 |
Why?
|
Heart Transplantation | 3 | 2019 | 3301 | 0.150 |
Why?
|
Retrospective Studies | 19 | 2024 | 81903 | 0.150 |
Why?
|
Myocardial Ischemia | 2 | 2021 | 2139 | 0.150 |
Why?
|
Positron-Emission Tomography | 4 | 2019 | 6673 | 0.150 |
Why?
|
Peripheral Arterial Disease | 3 | 2023 | 1304 | 0.150 |
Why?
|
Stents | 2 | 2009 | 3200 | 0.150 |
Why?
|
Canrenone | 1 | 2017 | 5 | 0.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 3253 | 0.140 |
Why?
|
Funnel Chest | 1 | 2018 | 75 | 0.140 |
Why?
|
Blood Glucose | 6 | 2024 | 6435 | 0.140 |
Why?
|
Electrophysiology | 1 | 2020 | 1266 | 0.140 |
Why?
|
Postoperative Period | 1 | 2022 | 1830 | 0.140 |
Why?
|
Health Status Disparities | 2 | 2019 | 1886 | 0.140 |
Why?
|
Age Factors | 10 | 2024 | 18435 | 0.140 |
Why?
|
Mortality | 4 | 2021 | 2914 | 0.140 |
Why?
|
Subclavian Artery | 1 | 2017 | 138 | 0.140 |
Why?
|
Blood Pressure Determination | 2 | 2019 | 646 | 0.140 |
Why?
|
Georgia (Republic) | 4 | 2018 | 39 | 0.140 |
Why?
|
Troponin | 3 | 2018 | 535 | 0.140 |
Why?
|
Pulmonary Edema | 2 | 2009 | 409 | 0.140 |
Why?
|
Electrodes, Implanted | 1 | 2021 | 841 | 0.140 |
Why?
|
Tachycardia, Ventricular | 3 | 2023 | 1309 | 0.140 |
Why?
|
Dyspnea | 5 | 2023 | 1352 | 0.130 |
Why?
|
Prostheses and Implants | 2 | 2024 | 1279 | 0.130 |
Why?
|
Activities of Daily Living | 3 | 2023 | 2434 | 0.130 |
Why?
|
Laboratories | 1 | 2020 | 463 | 0.130 |
Why?
|
Pacemaker, Artificial | 2 | 2019 | 828 | 0.130 |
Why?
|
Nutritional Status | 1 | 2024 | 1627 | 0.130 |
Why?
|
Methylprednisolone | 1 | 2017 | 386 | 0.130 |
Why?
|
Hypertrophy, Left Ventricular | 5 | 2017 | 856 | 0.130 |
Why?
|
Severity of Illness Index | 8 | 2021 | 15951 | 0.130 |
Why?
|
Micronutrients | 1 | 2019 | 390 | 0.130 |
Why?
|
Hospitals, Community | 1 | 2018 | 365 | 0.130 |
Why?
|
Gout | 1 | 2023 | 621 | 0.130 |
Why?
|
Leg | 2 | 2017 | 1089 | 0.130 |
Why?
|
Hospital Mortality | 5 | 2024 | 5369 | 0.130 |
Why?
|
Thyroid Diseases | 1 | 2019 | 385 | 0.130 |
Why?
|
Respiratory Rate | 1 | 2017 | 180 | 0.130 |
Why?
|
Natural Language Processing | 1 | 2024 | 1203 | 0.130 |
Why?
|
Heart Diseases | 1 | 2008 | 2819 | 0.120 |
Why?
|
Pyridazines | 1 | 2017 | 203 | 0.120 |
Why?
|
Anti-Obesity Agents | 1 | 2019 | 240 | 0.120 |
Why?
|
Cardiac Volume | 1 | 2015 | 197 | 0.120 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2019 | 881 | 0.120 |
Why?
|
Quality of Health Care | 3 | 2023 | 4339 | 0.120 |
Why?
|
Prednisone | 2 | 2017 | 1567 | 0.120 |
Why?
|
Echocardiography, Doppler | 3 | 2014 | 898 | 0.120 |
Why?
|
Dementia | 2 | 2020 | 2741 | 0.120 |
Why?
|
Device Removal | 1 | 2020 | 643 | 0.120 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 170 | 0.120 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3438 | 0.120 |
Why?
|
Lung | 2 | 2012 | 10099 | 0.120 |
Why?
|
Insulin | 3 | 2018 | 6610 | 0.120 |
Why?
|
Decision Trees | 1 | 2016 | 509 | 0.120 |
Why?
|
Multivariate Analysis | 6 | 2020 | 12095 | 0.110 |
Why?
|
Sarcopenia | 1 | 2019 | 377 | 0.110 |
Why?
|
Kansas | 2 | 2023 | 37 | 0.110 |
Why?
|
Emergency Service, Hospital | 2 | 2013 | 7957 | 0.110 |
Why?
|
Decision Support Systems, Clinical | 1 | 2023 | 1178 | 0.110 |
Why?
|
Dietary Proteins | 1 | 2019 | 960 | 0.110 |
Why?
|
Pharmacists | 1 | 2016 | 261 | 0.110 |
Why?
|
Internationality | 2 | 2019 | 1008 | 0.110 |
Why?
|
Carotid Arteries | 1 | 2017 | 943 | 0.110 |
Why?
|
Professional Role | 1 | 2016 | 316 | 0.110 |
Why?
|
Intermittent Positive-Pressure Ventilation | 1 | 2012 | 15 | 0.110 |
Why?
|
Frail Elderly | 1 | 2018 | 781 | 0.100 |
Why?
|
Adult | 25 | 2024 | 223851 | 0.100 |
Why?
|
Aldosterone | 2 | 2022 | 881 | 0.100 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2013 | 412 | 0.100 |
Why?
|
Electrophysiologic Techniques, Cardiac | 1 | 2015 | 511 | 0.100 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2018 | 644 | 0.100 |
Why?
|
Ultrasonography, Interventional | 2 | 2017 | 1524 | 0.100 |
Why?
|
Hemofiltration | 1 | 2012 | 58 | 0.100 |
Why?
|
Prevalence | 7 | 2024 | 15879 | 0.100 |
Why?
|
Electric Countershock | 1 | 2015 | 534 | 0.100 |
Why?
|
Cardiovascular System | 1 | 2020 | 841 | 0.100 |
Why?
|
Pulmonary Medicine | 1 | 2014 | 223 | 0.100 |
Why?
|
Arrhythmias, Cardiac | 3 | 2022 | 2258 | 0.100 |
Why?
|
Case-Control Studies | 6 | 2020 | 22296 | 0.100 |
Why?
|
Influenza A virus | 1 | 2015 | 460 | 0.100 |
Why?
|
Diet, Mediterranean | 1 | 2019 | 748 | 0.100 |
Why?
|
Cystatin C | 2 | 2023 | 272 | 0.100 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 2 | 2023 | 150 | 0.100 |
Why?
|
Sweden | 3 | 2020 | 1382 | 0.090 |
Why?
|
Social Behavior | 1 | 2018 | 1146 | 0.090 |
Why?
|
Coronary Vessels | 2 | 2018 | 3124 | 0.090 |
Why?
|
Fetal Death | 2 | 2009 | 434 | 0.090 |
Why?
|
Counseling | 1 | 2019 | 1554 | 0.090 |
Why?
|
Body Weight | 1 | 2021 | 4628 | 0.090 |
Why?
|
Diabetes Complications | 2 | 2020 | 1320 | 0.090 |
Why?
|
Athletes | 1 | 2018 | 1162 | 0.090 |
Why?
|
Research | 1 | 2019 | 1981 | 0.090 |
Why?
|
Hospitals | 2 | 2021 | 3904 | 0.090 |
Why?
|
Biopsy | 3 | 2017 | 6805 | 0.090 |
Why?
|
Patient Preference | 1 | 2018 | 947 | 0.090 |
Why?
|
Proteomics | 1 | 2024 | 3914 | 0.090 |
Why?
|
Latin America | 2 | 2024 | 416 | 0.090 |
Why?
|
Pregnancy Trimester, Third | 2 | 2009 | 586 | 0.090 |
Why?
|
Diabetic Cardiomyopathies | 1 | 2011 | 91 | 0.090 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2012 | 1724 | 0.090 |
Why?
|
Cohort Studies | 8 | 2024 | 41808 | 0.090 |
Why?
|
New York | 2 | 2023 | 884 | 0.090 |
Why?
|
Income | 1 | 2019 | 1879 | 0.090 |
Why?
|
Body Mass Index | 4 | 2024 | 13055 | 0.090 |
Why?
|
Statistics as Topic | 2 | 2015 | 2360 | 0.080 |
Why?
|
Cognition | 2 | 2024 | 7081 | 0.080 |
Why?
|
Logistic Models | 3 | 2020 | 13318 | 0.080 |
Why?
|
Tunica Intima | 1 | 2011 | 459 | 0.080 |
Why?
|
Pneumonia | 1 | 2021 | 2164 | 0.080 |
Why?
|
Case Management | 1 | 2011 | 277 | 0.080 |
Why?
|
Bariatric Surgery | 1 | 2019 | 1001 | 0.080 |
Why?
|
Thrombectomy | 1 | 2013 | 675 | 0.080 |
Why?
|
Catheter Ablation | 2 | 2015 | 2780 | 0.080 |
Why?
|
Heart Rate | 4 | 2023 | 4217 | 0.080 |
Why?
|
Data Collection | 1 | 2018 | 3324 | 0.080 |
Why?
|
Vaccination | 2 | 2022 | 3438 | 0.080 |
Why?
|
Ascorbic Acid | 1 | 2011 | 658 | 0.080 |
Why?
|
Outpatients | 3 | 2023 | 1603 | 0.070 |
Why?
|
Patients | 1 | 2014 | 908 | 0.070 |
Why?
|
Metformin | 1 | 2016 | 909 | 0.070 |
Why?
|
Administration, Oral | 1 | 2016 | 4040 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2784 | 0.070 |
Why?
|
Remission, Spontaneous | 1 | 2008 | 385 | 0.070 |
Why?
|
Treatment Failure | 4 | 2016 | 2664 | 0.070 |
Why?
|
Echocardiography, Transesophageal | 1 | 2013 | 1096 | 0.070 |
Why?
|
Equipment Design | 1 | 2015 | 3530 | 0.070 |
Why?
|
Pilot Projects | 2 | 2018 | 8748 | 0.070 |
Why?
|
Tachycardia | 1 | 2009 | 599 | 0.070 |
Why?
|
Weight Loss | 1 | 2019 | 2721 | 0.070 |
Why?
|
Population Surveillance | 1 | 2017 | 2597 | 0.070 |
Why?
|
Physical Examination | 3 | 2019 | 1262 | 0.070 |
Why?
|
Vitamin E | 1 | 2011 | 874 | 0.070 |
Why?
|
Survival Analysis | 5 | 2021 | 10115 | 0.070 |
Why?
|
Azetidines | 1 | 2008 | 152 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14794 | 0.070 |
Why?
|
Puerperal Disorders | 1 | 2009 | 304 | 0.070 |
Why?
|
Up-Regulation | 1 | 2016 | 4148 | 0.070 |
Why?
|
Renal Dialysis | 1 | 2016 | 1789 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2023 | 4712 | 0.070 |
Why?
|
Ventricular Outflow Obstruction | 1 | 2008 | 262 | 0.060 |
Why?
|
Radiopharmaceuticals | 2 | 2019 | 2734 | 0.060 |
Why?
|
Extracellular Matrix | 1 | 2013 | 1739 | 0.060 |
Why?
|
Simvastatin | 1 | 2008 | 346 | 0.060 |
Why?
|
Sleep | 1 | 2021 | 4820 | 0.060 |
Why?
|
Urinalysis | 2 | 2018 | 370 | 0.060 |
Why?
|
Surgical Instruments | 1 | 2008 | 386 | 0.060 |
Why?
|
Boston | 2 | 2016 | 9377 | 0.060 |
Why?
|
South America | 2 | 2016 | 180 | 0.060 |
Why?
|
Medication Adherence | 1 | 2017 | 2192 | 0.060 |
Why?
|
Circadian Rhythm | 1 | 2017 | 2593 | 0.060 |
Why?
|
Anticoagulants | 3 | 2023 | 4850 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7861 | 0.060 |
Why?
|
Propanolamines | 1 | 2005 | 164 | 0.060 |
Why?
|
Vasodilator Agents | 2 | 2022 | 990 | 0.060 |
Why?
|
ROC Curve | 1 | 2012 | 3629 | 0.060 |
Why?
|
Sodium-Glucose Transport Proteins | 1 | 2024 | 13 | 0.060 |
Why?
|
Curriculum | 2 | 2015 | 3782 | 0.060 |
Why?
|
Receptors, Cell Surface | 1 | 2013 | 2820 | 0.060 |
Why?
|
Fluoroscopy | 1 | 2008 | 947 | 0.060 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1737 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2018 | 3447 | 0.060 |
Why?
|
Blood Urea Nitrogen | 1 | 2024 | 189 | 0.060 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4862 | 0.060 |
Why?
|
Argentina | 2 | 2016 | 249 | 0.060 |
Why?
|
Carbazoles | 1 | 2005 | 230 | 0.050 |
Why?
|
Atmosphere | 1 | 2023 | 32 | 0.050 |
Why?
|
Drug Substitution | 2 | 2016 | 291 | 0.050 |
Why?
|
Hypovolemia | 1 | 2023 | 48 | 0.050 |
Why?
|
Pre-Eclampsia | 2 | 2009 | 1255 | 0.050 |
Why?
|
Vascular Diseases | 1 | 2011 | 1163 | 0.050 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 2422 | 0.050 |
Why?
|
Aptamers, Nucleotide | 1 | 2024 | 163 | 0.050 |
Why?
|
Postpartum Period | 1 | 2009 | 1198 | 0.050 |
Why?
|
Calcium | 1 | 2016 | 5792 | 0.050 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2012 | 1189 | 0.050 |
Why?
|
Diagnostic Errors | 1 | 2009 | 1281 | 0.050 |
Why?
|
Beds | 1 | 2021 | 48 | 0.050 |
Why?
|
Critical Care | 1 | 2014 | 2716 | 0.050 |
Why?
|
Cardiac Surgical Procedures | 1 | 2017 | 3683 | 0.050 |
Why?
|
Atherosclerosis | 1 | 2017 | 3431 | 0.050 |
Why?
|
Headache | 1 | 2009 | 1264 | 0.050 |
Why?
|
Colchicine | 1 | 2023 | 257 | 0.050 |
Why?
|
Exercise | 1 | 2018 | 5954 | 0.050 |
Why?
|
Asymptomatic Diseases | 1 | 2024 | 590 | 0.050 |
Why?
|
Fatigue | 2 | 2020 | 1557 | 0.050 |
Why?
|
Probability | 2 | 2021 | 2483 | 0.050 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2023 | 462 | 0.050 |
Why?
|
Canada | 2 | 2017 | 2130 | 0.050 |
Why?
|
Animals | 3 | 2020 | 169335 | 0.050 |
Why?
|
Glucose | 2 | 2022 | 4352 | 0.040 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5544 | 0.040 |
Why?
|
Remote Sensing Technology | 1 | 2021 | 93 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2023 | 691 | 0.040 |
Why?
|
Ventricular Fibrillation | 1 | 2023 | 537 | 0.040 |
Why?
|
Vaccines, Inactivated | 1 | 2021 | 186 | 0.040 |
Why?
|
Amyloidosis | 1 | 2008 | 879 | 0.040 |
Why?
|
Inpatients | 2 | 2023 | 2569 | 0.040 |
Why?
|
Warfarin | 1 | 2008 | 1493 | 0.040 |
Why?
|
Pregnancy | 3 | 2010 | 30265 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2009 | 2339 | 0.040 |
Why?
|
Asia, Western | 1 | 2018 | 19 | 0.040 |
Why?
|
C-Reactive Protein | 2 | 2024 | 3859 | 0.040 |
Why?
|
Ultrasonography | 1 | 2012 | 6002 | 0.040 |
Why?
|
Europe, Eastern | 1 | 2018 | 72 | 0.040 |
Why?
|
Cholesterol, LDL | 2 | 2021 | 2403 | 0.040 |
Why?
|
Self Efficacy | 1 | 2023 | 643 | 0.040 |
Why?
|
Liver Cirrhosis | 1 | 2009 | 1962 | 0.040 |
Why?
|
Asia, Southeastern | 1 | 2018 | 115 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 36854 | 0.040 |
Why?
|
Quebec | 1 | 2018 | 139 | 0.040 |
Why?
|
Registries | 3 | 2020 | 8384 | 0.040 |
Why?
|
Americas | 1 | 2018 | 110 | 0.040 |
Why?
|
Cost of Illness | 2 | 2020 | 1960 | 0.040 |
Why?
|
Mitral Valve Insufficiency | 1 | 2008 | 1415 | 0.040 |
Why?
|
Recurrence | 3 | 2018 | 8513 | 0.040 |
Why?
|
Biological Availability | 1 | 2019 | 392 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2019 | 131 | 0.040 |
Why?
|
Angioedema | 1 | 2019 | 184 | 0.040 |
Why?
|
Digoxin | 1 | 2018 | 246 | 0.040 |
Why?
|
Nausea | 1 | 2020 | 682 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2010 | 13021 | 0.040 |
Why?
|
Medicare | 3 | 2024 | 6888 | 0.040 |
Why?
|
Asia | 1 | 2018 | 630 | 0.030 |
Why?
|
Cheyne-Stokes Respiration | 1 | 2017 | 38 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 878 | 0.030 |
Why?
|
Japan | 1 | 2021 | 1418 | 0.030 |
Why?
|
Transducers, Pressure | 1 | 2016 | 51 | 0.030 |
Why?
|
Protein Precursors | 1 | 2020 | 1135 | 0.030 |
Why?
|
Recovery of Function | 2 | 2017 | 2990 | 0.030 |
Why?
|
Placebos | 1 | 2020 | 1667 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2010 | 4978 | 0.030 |
Why?
|
Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2016 | 131 | 0.030 |
Why?
|
Wireless Technology | 1 | 2016 | 102 | 0.030 |
Why?
|
Young Adult | 4 | 2017 | 60131 | 0.030 |
Why?
|
Credentialing | 1 | 2015 | 114 | 0.030 |
Why?
|
Heart Conduction System | 1 | 2020 | 1009 | 0.030 |
Why?
|
Polysomnography | 1 | 2021 | 1871 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2023 | 1673 | 0.030 |
Why?
|
Sarcomeres | 1 | 2017 | 380 | 0.030 |
Why?
|
RNA | 1 | 2024 | 2727 | 0.030 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2014 | 169 | 0.030 |
Why?
|
Needs Assessment | 1 | 2019 | 1143 | 0.030 |
Why?
|
USSR | 1 | 2012 | 19 | 0.030 |
Why?
|
Linear Models | 2 | 2016 | 5891 | 0.030 |
Why?
|
Length of Stay | 2 | 2020 | 6526 | 0.030 |
Why?
|
Age Distribution | 1 | 2018 | 2875 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2019 | 965 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1119 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2017 | 620 | 0.030 |
Why?
|
Carbon Dioxide | 1 | 2017 | 1149 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2023 | 5323 | 0.030 |
Why?
|
Cholesterol | 1 | 2021 | 2913 | 0.020 |
Why?
|
Australia | 1 | 2016 | 1265 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2022 | 2649 | 0.020 |
Why?
|
Diffusion of Innovation | 1 | 2017 | 732 | 0.020 |
Why?
|
Brazil | 1 | 2016 | 1250 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22389 | 0.020 |
Why?
|
Drug Interactions | 1 | 2016 | 1418 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2020 | 20245 | 0.020 |
Why?
|
Propensity Score | 1 | 2019 | 1968 | 0.020 |
Why?
|
Netherlands | 1 | 2016 | 2277 | 0.020 |
Why?
|
Placebo Effect | 1 | 2015 | 518 | 0.020 |
Why?
|
Dependovirus | 1 | 2016 | 721 | 0.020 |
Why?
|
Decision Making | 1 | 2024 | 3953 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2350 | 0.020 |
Why?
|
Intention to Treat Analysis | 1 | 2011 | 417 | 0.020 |
Why?
|
Glucose Clamp Technique | 1 | 2010 | 263 | 0.020 |
Why?
|
Health Care Costs | 1 | 2003 | 3270 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2018 | 997 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2666 | 0.020 |
Why?
|
Losartan | 1 | 2011 | 262 | 0.020 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2009 | 173 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1672 | 0.020 |
Why?
|
Amlodipine | 1 | 2009 | 84 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2011 | 684 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2015 | 1820 | 0.020 |
Why?
|
Amiodarone | 1 | 2010 | 217 | 0.020 |
Why?
|
Hypoglycemia | 1 | 2016 | 895 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9684 | 0.020 |
Why?
|
Regression Analysis | 1 | 2018 | 6346 | 0.020 |
Why?
|
Bumetanide | 1 | 2008 | 101 | 0.020 |
Why?
|
New England | 1 | 2011 | 1058 | 0.020 |
Why?
|
Radial Artery | 1 | 2009 | 188 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2020 | 3628 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3709 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2016 | 1602 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8559 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2018 | 3726 | 0.020 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2018 | 1568 | 0.020 |
Why?
|
Triglycerides | 1 | 2015 | 2464 | 0.020 |
Why?
|
Depression | 2 | 2020 | 8231 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9621 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7245 | 0.020 |
Why?
|
Manometry | 1 | 2009 | 459 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1642 | 0.020 |
Why?
|
Thromboembolism | 1 | 2013 | 1004 | 0.020 |
Why?
|
Shock, Septic | 1 | 2013 | 774 | 0.020 |
Why?
|
Developing Countries | 1 | 2019 | 2911 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2016 | 3412 | 0.020 |
Why?
|
Organ Size | 1 | 2011 | 2268 | 0.020 |
Why?
|
Biological Transport | 1 | 2010 | 2085 | 0.020 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2010 | 775 | 0.020 |
Why?
|
Models, Statistical | 1 | 2020 | 5110 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6856 | 0.020 |
Why?
|
Heart | 1 | 2018 | 4447 | 0.010 |
Why?
|
Creatine Kinase, MB Form | 1 | 2004 | 202 | 0.010 |
Why?
|
Smoking | 1 | 2021 | 9094 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2862 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2383 | 0.010 |
Why?
|
Inflammation | 1 | 2024 | 10868 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14752 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2011 | 2437 | 0.010 |
Why?
|
Adolescent | 3 | 2017 | 89244 | 0.010 |
Why?
|
Kinetics | 1 | 2010 | 6332 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2008 | 971 | 0.010 |
Why?
|
Creatine Kinase | 1 | 2004 | 684 | 0.010 |
Why?
|
Life Expectancy | 1 | 2009 | 1249 | 0.010 |
Why?
|
Lower Extremity | 1 | 2010 | 1217 | 0.010 |
Why?
|
Myocarditis | 1 | 2010 | 803 | 0.010 |
Why?
|
Genotype | 1 | 2017 | 13048 | 0.010 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2014 | 2763 | 0.010 |
Why?
|
Life Style | 1 | 2012 | 3931 | 0.010 |
Why?
|
Isoenzymes | 1 | 2004 | 1687 | 0.010 |
Why?
|
Clinical Competence | 1 | 2015 | 4860 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 26395 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2011 | 4207 | 0.010 |
Why?
|
Radiography | 1 | 2009 | 6991 | 0.010 |
Why?
|
Sulfonamides | 1 | 2008 | 1981 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2009 | 3492 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2010 | 3982 | 0.010 |
Why?
|
Mutation | 1 | 2017 | 30266 | 0.010 |
Why?
|
Child | 1 | 2017 | 80960 | 0.000 |
Why?
|